INVESTOR ALERT: Former Attorney General Of Louisiana And Kahn Swick & Foti, LLC Investigate Impax Laboratories Inc. Following Announcement Of The FDA’s Negative Review Of Hayward Plant And Trading Halt

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC announce that KSF has commenced an investigation into Impax Laboratories Inc. (Nasdaq: IPXL).

Shares of Impax Labs was halted in aftermarket trading following Company’s announcement that the Food and Drug Administration issued a new Form 483 with twelve (12) observations, three (3) of which are designated as repeat observations from inspections that occurred prior to the Warning Letter. According to the Company, until remedial action is complete and the FDA has confirmed compliance with current Good Manufacturing Procedures, approval of pending and new applications listing the Hayward facility as a manufacturing location of finished dosage forms may be withheld.

KSF’s investigation is focusing on whether Impax Labs and/or its officers and directors violated state or federal securities laws.

If you have information that would assist KSF in its investigation, or would like to discuss your legal rights, you may, without obligation or cost to you, e-mail or call KSF Managing Partner, Lewis Kahn ( lewis.kahn@ksfcounsel.com), toll free, 877-515-1850, or via cell phone any time at 504-301-7900.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities class action and shareholder derivative litigation with offices in New York and Louisiana. KSF's lawyers have significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders.

To learn more about KSF, you may visit www.ksfcounsel.com.

Copyright Business Wire 2010

If you liked this article you might like

Impax Shares Jump on Merger Buzz

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades